185 related articles for article (PubMed ID: 29748619)
1. Eukaryotic Translation Initiation Factor 4 Gamma 1 (eIF4G1) is upregulated during Prostate cancer progression and modulates cell growth and metastasis.
Jaiswal PK; Koul S; Shanmugam PST; Koul HK
Sci Rep; 2018 May; 8(1):7459. PubMed ID: 29748619
[TBL] [Abstract][Full Text] [Related]
2. Eukaryotic Translation Initiation Factor 4 Gamma 1 (EIF4G1): a target for cancer therapeutic intervention?
Jaiswal PK; Koul S; Palanisamy N; Koul HK
Cancer Cell Int; 2019; 19():224. PubMed ID: 31496918
[TBL] [Abstract][Full Text] [Related]
3. Over-expression of eukaryotic translation initiation factor 4 gamma 1 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma.
Tu L; Liu Z; He X; He Y; Yang H; Jiang Q; Xie S; Xiao G; Li X; Yao K; Fang W
Mol Cancer; 2010 Apr; 9():78. PubMed ID: 20398343
[TBL] [Abstract][Full Text] [Related]
4. Elevation of EIF4G1 promotes non-small cell lung cancer progression by activating mTOR signalling.
Lu Y; Yu S; Wang G; Ma Z; Fu X; Cao Y; Li Q; Xu Z
J Cell Mol Med; 2021 Mar; 25(6):2994-3005. PubMed ID: 33523588
[TBL] [Abstract][Full Text] [Related]
5. Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.
Neuwirt H; Bouchal J; Kharaishvili G; Ploner C; Jöhrer K; Pitterl F; Weber A; Klocker H; Eder IE
Cell Commun Signal; 2020 Jan; 18(1):11. PubMed ID: 31980029
[TBL] [Abstract][Full Text] [Related]
6. Functional role of eukaryotic translation initiation factor 4 gamma 1 (EIF4G1) in NSCLC.
Cao Y; Wei M; Li B; Liu Y; Lu Y; Tang Z; Lu T; Yin Y; Qin Z; Xu Z
Oncotarget; 2016 Apr; 7(17):24242-51. PubMed ID: 27003362
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding RNA LINC00963 induces NOP2 expression by sponging tumor suppressor miR-542-3p to promote metastasis in prostate cancer.
Sun F; Wu K; Yao Z; Mu X; Zheng Z; Sun M; Wang Y; Liu Z; Zhu Y
Aging (Albany NY); 2020 Jun; 12(12):11500-11516. PubMed ID: 32554858
[TBL] [Abstract][Full Text] [Related]
8. Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
Sun W; Li L; Du Z; Quan Z; Yuan M; Cheng H; Gao Y; Luo C; Wu X
Oncol Rep; 2019 May; 41(5):2689-2702. PubMed ID: 30864728
[TBL] [Abstract][Full Text] [Related]
9. Role of EIF4G1 network in non-small cell lung cancers (NSCLC) cell survival and disease progression.
Del Valle L; Dai L; Lin HY; Lin Z; Chen J; Post SR; Qin Z
J Cell Mol Med; 2021 Mar; 25(6):2795-2805. PubMed ID: 33539648
[TBL] [Abstract][Full Text] [Related]
10. p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance.
Miller DR; Ingersoll MA; Chatterjee A; Baker B; Shrishrimal S; Kosmacek EA; Zhu Y; Cheng PW; Oberley-Deegan RE; Lin MF
Free Radic Biol Med; 2019 Aug; 139():24-34. PubMed ID: 31100478
[TBL] [Abstract][Full Text] [Related]
11. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
[TBL] [Abstract][Full Text] [Related]
12.
Chen X; Ma J; Wang X; Zi T; Qian D; Li C; Xu C
Front Endocrinol (Lausanne); 2022; 13():1106175. PubMed ID: 36601001
[TBL] [Abstract][Full Text] [Related]
13. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S
Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300
[TBL] [Abstract][Full Text] [Related]
14. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
Maina PK; Shao P; Liu Q; Fazli L; Tyler S; Nasir M; Dong X; Qi HH
Oncotarget; 2016 Nov; 7(46):75585-75602. PubMed ID: 27689328
[TBL] [Abstract][Full Text] [Related]
15. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
16. The ERα-NRF2 signalling axis promotes bicalutamide resistance in prostate cancer.
Tian L; Peng Y; Yang K; Cao J; Du X; Liang Z; Shi J; Zhang J
Cell Commun Signal; 2022 Nov; 20(1):178. PubMed ID: 36376959
[TBL] [Abstract][Full Text] [Related]
17. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
Guan Y; Wu Y; Liu Y; Ni J; Nong S
Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
[TBL] [Abstract][Full Text] [Related]
18. Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity.
Ding G; Wang J; Feng C; Jiang H; Xu J; Ding Q
Oncotarget; 2016 Sep; 7(39):64309-64317. PubMed ID: 27602760
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer.
Rönnau CGH; Fussek S; Smit FP; Aalders TW; van Hooij O; Pinto PMC; Burchardt M; Schalken JA; Verhaegh GW
World J Urol; 2021 Oct; 39(10):3789-3797. PubMed ID: 33990872
[TBL] [Abstract][Full Text] [Related]
20. CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway.
Ji J; Shen T; Li Y; Liu Y; Shang Z; Niu Y
Oncol Rep; 2021 Mar; 45(3):921-932. PubMed ID: 33650660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
